Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

DPAG Professor one of three researchers from Oxford University who received prestigious awards from the Royal Society in recognition of their work in the fields of science and medicine.

The Croonian Medal and Lecture has been awarded to Professor Dame Kay Davies FMedSci FRS of Oxford’s Department of Physiology, Anatomy and Genetics (DPAG) for her achievements in developing a prenatal test for Duchenne muscular dystrophy and for her work characterising the binding partners of the protein dystr-ophin. 

Duchenne muscular dystrophy is a progressive muscle wasting disease which affects mostly boys, who often need wheelchairs at about 12 years of age and die in their twenties, usually from respiratory or cardiac problems. There is currently no effective treatment. Kay’s work has resulted in treatments poised to transform the lives of an estimate 250,000 patients worldwide.

Professor Tamsin Mather, Professor of Earth Science at the University of Oxford, was awarded the Rosalind Franklin Award for her work in the field of volcanology, and Professor Ian Walmsley FRS of Oxford’s Department of Physics was awarded the Rumford Medal for his pioneering work in the quantum control of light and matter on ultrashort timescales.

Find out more (University of Oxford website)

Similar stories

Prestigious award for Oxford professor's diabetes work

A University of Oxford professor has been awarded the 2021 EASD-Novo Nordisk Foundation Prize for Excellence for his decades of effort to understand, prevent and combat type 1 diabetes.

Wellcome accolades for Dr Douglas

Dr Alexander (Sandy) Douglas, an investigator at the Jenner Institute, Nuffield Department of Medicine, has recently received two prestigious Wellcome accolades.

FOCUS4: a flagship trial in colorectal cancer

Professor Tim Maughan (Department of Oncology) outlines the flagship work of the FOCUS4 trials, whose results were presented last weekend at the European Society of Medical Oncology (ESMO) annual meeting

Oxford and Oracle partner to speed identification of COVID-19 variants

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle’s Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include: the University of Montreal Hospital Centre Research Centre, the Institute of Public Health Research of Chile, the Oxford University Clinical Research Unit in Vietnam, the Institute of Clinical Pathology and Medical Research – New South Wales Pathology, and Oxford Nanopore Technologies. GPAS is also now part of the Public Health England New Variant Assessment Platform.

Vaccinated groups at highest risk of Covid-19 hospitalisation and death identified using new QCovid tool

Researchers from the University of Oxford have today reported on findings on the vaccinated people who are at greatest risk from severe Covid-19 leading to hospitalisation or death from 14 days post the second dose vaccination, when substantial immunity should be expected.